sb-t-1216

SB-T-1216 is a **second-generation synthetic taxane derivative** (taxoid), designed for high efficacy against multidrug-resistant cancers, particularly ovarian carcinoma and pancreatic ductal adenocarcinoma. It is part of the Stony Brook Taxane (SB-T) family, with further chemically modified "third-generation" analogs such as SB-T-121605 and SB-T-121606 developed for improved efficacy and reduced toxicity[1][3]. SB-T-1216 acts by stabilizing microtubules and arresting the cell cycle in the G2/M phase, leading to apoptosis of cancer cells. It shows significantly higher activity than paclitaxel (PTX), especially in resistant cell lines, and accumulates intracellularly at higher concentrations. SB-T-1216's main mechanism is inhibition of microtubule depolymerization, similar to classical taxanes. Its primary indications explored are drug-resistant ovarian carcinoma and pancreatic ductal adenocarcinoma, with results from *in vitro* and xenograft *in vivo* models[1][3].

Brand names

SB-T-1216SB-T1216SB-T 1216

Other names

SB-T-1216SB-T1216SB-T 1216